Cambridge Nucleomics utilizes proprietary nanostructure design technology to create customized molecular probes for the accurate and direct quantification of native RNA, including short non-coding RNA like miRNA. This approach addresses the limitations of current RNA detection methods, which often involve biases, lengthy protocols, and high costs, enabling faster and more reliable measurements essential for drug discovery and RNA-based diagnostics.
Funding
$340K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current RNA detection and quantification methods often suffer from biases, long running times, complicated protocols, low multiplexing, and high costs. These problems are exacerbated for short non-coding RNA, such as miRNA, due to the need for enzymatic modifications of the target prior to processing.
Solution
Cambridge Nucleomics provides a technology for the accurate and direct quantification of native RNA, including short non-coding RNA like miRNA. The company's proprietary nanostructure design technology enables the creation of customized molecular probes that recognize specific nucleic acid molecules and detect them natively. Specific signals from the resulting sample are then digitized using a single-molecule readout technique. This approach allows for direct measurement of the original target molecules without complicated sample processing.
Target Audience
The primary customers are big pharma, biotech companies, and clinical researchers involved in drug discovery and RNA-based diagnostics and prognostics.
Features
- Custom molecular probes designed to recognize specific nucleic acid molecules.
- Direct measurement of native RNA molecules without enzymatic modifications.
- Single-molecule readout technique for signal digitization.
- High-multiplexing capabilities for simultaneous detection of multiple RNA targets.
- Suitable for the detection of other biomolecules such as DNA.